Biogen

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

Retrieved on: 
Tuesday, October 12, 2021
NTM, NDA, Biogen, AP, Foreign policy, Therapy, Pyelonephritis, Harvard Kennedy School, Biotechnology, COVID-19, GLOBE, Cutis marmorata telangiectatica congenita, Growth, Board of directors, Stanford University, MDR, Board, FDA, U.S. Securities and Exchange Commission, International relations, Urinary tract infection, Public policy, Congress, Policy, Senior, Corporate Affairs, Degenerative disease, HBR, Infection, Government Affairs Institute, Tebipenem, Government, Patient, Nasdaq, Drug of last resort, Pharmaceutical industry, Management

Currently the Chief Corporate Affairs Officer at Cerevel Therapeutics, Ms. Tregoning has more than two decades of experience in biotechnology and public policy.

Key Points: 
  • Currently the Chief Corporate Affairs Officer at Cerevel Therapeutics, Ms. Tregoning has more than two decades of experience in biotechnology and public policy.
  • Kathleen is an accomplished industry leader, and we are honored to welcome her to our Board, said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • Spero is bringing true innovation to the critical issue of multi-drug resistant infections, and I am delighted to be joining the Board at such an exciting time, said Ms. Tregoning.
  • Spero Therapeutics, Inc.is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer

Retrieved on: 
Tuesday, October 12, 2021
Biotechnology, Health, Oncology, Clinical Trials, Tumor microenvironment, History, GPS, Therapy, Catholic higher education, Biogen, Biotechnology, Program, Culture, Columbus School of Law, Time, Cancer, Ethics committee, Merck & Co., Captain America, Cell therapy, Cytokine, Board, Society, Cubist Pharmaceuticals, Infection, Immune system, Policy, Philosophy, Gene, Leadership, Therapeutic index, Acquisition, Patient, Pharming, Pharmaceutical industry

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that Timothy D. Hunt has been appointed as the companys chief culture and corporate affairs officer.

Key Points: 
  • Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that Timothy D. Hunt has been appointed as the companys chief culture and corporate affairs officer.
  • In this role, Mr. Hunt will serve as a member of the executive team and will oversee human resources, communications and other strategic initiatives.
  • D., president and chief executive officer of Xilio.
  • Mr. Hunt brings more than 20 years of biotechnology experience to Xilio, most recently serving as chief corporate affairs officer at Editas Medicine, Inc. (Editas) where he oversaw the human resources, market development and early-stage commercial planning, policy and government affairs, and corporate communications functions from 2016 to 2020.

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Retrieved on: 
Tuesday, October 12, 2021
Company, CNRS, Biogen, Eli Lilly and Company, INSEAD, Therapy, CSO, Pasteur Institute, Doctor of Philosophy, Central nervous system, General manager, Biotechnology, MBA, Board of directors, Industry, Kadmon Corporation, Genzyme, ATyr Pharma, Research, Board, Gene editing, Neurological disorder, Center, COO, Lists of diseases, AAV, Gene, National Centre for Disease Control, Senior, Degenerative disease, Paris Diderot University, Science, CEO, Principal, CNS, Master of Science, Bachelor of Science, UCL, Pharmaceutical industry, Vaccine, Management

PARIS, Oct. 12, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces the appointment of Dr. Olivier Danos PhD and Frederic Chereau MBA to the Company's Board of Directors, as independent non-executive directors.

Key Points: 
  • PARIS, Oct. 12, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces the appointment of Dr. Olivier Danos PhD and Frederic Chereau MBA to the Company's Board of Directors, as independent non-executive directors.
  • "We are thrilled to have two highly experienced biotech executives with gene therapy knowledge and corporate leadership join the Board of Coave.
  • Olivier and Frederic have tremendous international experience in the gene therapy field and their willingness to join our Board is recognition of the Company's potential," said Benedikt Timmerman, Chair of Coave Therapeutics' Board.
  • "I am delighted to welcome both Olivier and Frederic to Coave's Board," added Rodolphe Clerval, CEO of Coave.

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Retrieved on: 
Tuesday, October 12, 2021
Company, CNRS, Biogen, Eli Lilly and Company, INSEAD, Therapy, CSO, Pasteur Institute, Doctor of Philosophy, Central nervous system, General manager, Biotechnology, MBA, Board of directors, Industry, Kadmon Corporation, Genzyme, ATyr Pharma, Research, Board, Gene editing, Neurological disorder, Center, COO, Lists of diseases, AAV, Gene, National Centre for Disease Control, Senior, Degenerative disease, Paris Diderot University, Science, CEO, Principal, CNS, Master of Science, Bachelor of Science, UCL, Pharmaceutical industry, Vaccine, Management

PARIS, Oct. 12, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces the appointment of Dr. Olivier Danos PhD and Frederic Chereau MBA to the Company's Board of Directors, as independent non-executive directors.

Key Points: 
  • PARIS, Oct. 12, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces the appointment of Dr. Olivier Danos PhD and Frederic Chereau MBA to the Company's Board of Directors, as independent non-executive directors.
  • "We are thrilled to have two highly experienced biotech executives with gene therapy knowledge and corporate leadership join the Board of Coave.
  • Olivier and Frederic have tremendous international experience in the gene therapy field and their willingness to join our Board is recognition of the Company's potential," said Benedikt Timmerman, Chair of Coave Therapeutics' Board.
  • "I am delighted to welcome both Olivier and Frederic to Coave's Board," added Rodolphe Clerval, CEO of Coave.

Post-Launch Insights Point to Four Key Factors That Could Drive Future Use of Biogen/Eisai's Aduhelm in Alzheimer's Disease, According to Spherix Global Insights

Retrieved on: 
Thursday, October 7, 2021
Nephrology, Center, Biogen, EMERGE, MCI, Neurology, Cleveland Clinic, Physician, Cleveland, Cognition, Safety, DMT, DMTS, Education, MRI, FDA, CMS, Medicare, Eli Lilly and Company, Benchmarking, PET, Centers for Medicare & Medicaid Services, Amyloid, Patient, Clinical trial, Research, ARIA, Eisai, Dementia, Pharmaceutical industry, Medical imaging, Generic drug

Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever prescribed it, remain low.

Key Points: 
  • Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever prescribed it, remain low.
  • According to one interviewed neurologist, "I'm hesitant about [Aduhelm] at this point because I don't have enough education on it."
  • The decision of certain large centers, such as the Cleveland Clinic, not to infuse Aduhelm has also made neurologists cautious about prescribing Aduhelm.
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

Global mRNA Market (2021 to 2026) - Featuring Amgen, Arcturus Therapeutics and Crispr Therapeutics Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Pharmaceutical, Health, Adoption, Infection, Propionic acidemia, RNA transfection, Vaccine, Therapy, Biogen, Cancer, Degenerative disease, BioNTech, Biology, Lists of diseases, Phenylketonuria, Growth, Prevalence, COVID-19, CKD, Conditional sentence, Amgen, Incidence, Methylmalonic acidemia, HIV, Industry, Protein

mRNA therapeutics typically include vaccines, drugs and therapies developed through mRNA technology.

Key Points: 
  • mRNA therapeutics typically include vaccines, drugs and therapies developed through mRNA technology.
  • This market growth is fueled by the increasing incidence of infectious diseases (e.g., COVID-19, Zika, influenza, Ebola, etc.
  • The market for 2020 is relatively lower since BioNTech and Moderna received emergency approvals for their vaccines in December 2020.
  • The U.S. is expected to maintain dominance in the mRNA therapeutics market.

Japanese Pharmaceutical Group Kyowa Kirin Selects the Generis CARA™ Life Science Platform for Global Regulatory Correspondence Management

Retrieved on: 
Wednesday, October 6, 2021
Language, Content, RIM, Kyowa Hakko Kirin, Review, CMC, Biogen, Patient, Engineering, Information management, Merck, Life, Generis, Nephrology, AstraZeneca, Data management, Neurology, Automation, Research, Asia, CARA, AbbVie, Risk management, Fine chemical, Medical device, Pharmaceutical industry

LONDON, Oct. 6, 2021 /PRNewswire-PRWeb/ --The company has adopted Generis' CARA platform for ongoing work to answer questions from healthcare authorities around the world, leveraging the powerful automation and translation capabilities of the CARA Life Science Platform to capture, review and answer regulatory questions.

Key Points: 
  • LONDON, Oct. 6, 2021 /PRNewswire-PRWeb/ --The company has adopted Generis' CARA platform for ongoing work to answer questions from healthcare authorities around the world, leveraging the powerful automation and translation capabilities of the CARA Life Science Platform to capture, review and answer regulatory questions.
  • The CARA Life Sciences Platform has seen a flurry of activity over the past few months as pharmaceutical companies seek to streamline the management and publication of regulatory, quality, safety and clinical information/content using a consistent global platform that can be easily configured to suit each new use case.
  • You can learn more about the business of Kyowa Kirin at https://www.kyowakirin.com
    Generis is a UK-headquartered developer of world-class Content and Data Management technology for regulated industries globally.
  • 60% of the top 20 life sciences companies rely on Generis' flagship CARA Life Science Platform for critical document and information management, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer, and Merck KGaA.

Aktana Launches Contextual Intelligence 360 to Solve the Challenge of Personalizing Customer Engagement at Scale

Retrieved on: 
Wednesday, October 6, 2021
Open Platform, Adoption, Goal, News, Trust, Solution, Workflow, HCPS, Logic, Biogen, Software, Physician, Health, AI, Organization, SAN, Intelligence, Contextual, Industry, Theory of multiple intelligences, GLOBE, Management

Contextual Intelligence 360 builds on Aktanas legacy AI strength in sales channel optimization to bring the same level of machine learning precision and contextual insights to all commercial activities.

Key Points: 
  • Contextual Intelligence 360 builds on Aktanas legacy AI strength in sales channel optimization to bring the same level of machine learning precision and contextual insights to all commercial activities.
  • Now, as the use of digital is skyrocketing and HCPs are time-constrained like never before, coordinated omnichannel engagement with HCPs is crucial for success.
  • Aktanas Contextual Intelligence 360 includes the following components:
    HCP Engagement AI Pre-built machine learning modules dynamically identify individual customer preferences across content, channel, and timing.
  • Today, commercial and medical teams from nearly 300 brands use Aktanas AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale.

Life Clips Subsidiary Cognitive Apps To Benefit From Apple's iPhone Features to Help Detect Depression, Cognitive Decline

Retrieved on: 
Tuesday, October 5, 2021
Human, Private Securities Litigation Reform Act, Overalls, University, App, Mental health, Apple Watch, Intelligence, Social anxiety, Attention, Failure, The Wall Street Journal, Depression, Cognitive behavioral therapy, Alzheimer's disease, Android, Media, Psychotherapy, CEO, Government budget balance, Dementia, Awareness, CBT, Aiki, Cryptocurrency, PTSD, Anxiety, UCLA, Eli Lilly, OTC Markets Group, IPhone, FDA, Occupational burnout, Gartner, Company, University of California Television, Life, Emotion, Yuru, Forward-looking statement, Time, Government, GLOBE, Patent, Sleep, Biogen, Patient, Biomarker, IPT, Algorithm, Research, Mobile phone

Apples initiation provides a tremendous boost to the mental health industry market that is beneficial for each market player.

Key Points: 
  • Apples initiation provides a tremendous boost to the mental health industry market that is beneficial for each market player.
  • In an effort to make its diagnostic tool more accurate, Cognitive Apps uses voice biomarkers and analyses context to detect emotions and overall mental state.
  • We see big tech entering the mental health sector and using their huge resources to tackle social anxiety and depression as a big win for both Cognitive Apps and Life Clips.
  • We believe this offers tremendous proof of concept for Cognitive Apps speech-based, AI-powered mental health analytics platform.

Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on: 
Monday, October 4, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, the Short-Form Health Survey (SF-36), Major Depressive Disorder (MDD), Zuranolone, Sage Therapeutics, Biogen, THE SHORT-FORM HEALTH SURVEY (SF-36), MAJOR DEPRESSIVE DISORDER (MDD), ZURANOLONE, SAGE THERAPEUTICS, BIOGEN

The collection of data presented at ECNP showcases the LANDSCAPE and NEST programs, in totality, where we have seen a very consistent and differentiated profile for zuranolone.

Key Points: 
  • The collection of data presented at ECNP showcases the LANDSCAPE and NEST programs, in totality, where we have seen a very consistent and differentiated profile for zuranolone.
  • The efficacy data across the clinical development programs have demonstrated a rapid onset of activity, consistent reductions in depressive symptoms and a two-week treatment regimen that may offer the potential to treat-as-needed.
  • Patients in the trials are also indicating through the patient outcome measures that zuranolone helped with their overall well-being.
  • Zuranolone is being evaluated as a potential rapid-acting treatment for PPD and MDD in the NEST and LANDSCAPE clinical trial programs.